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ABSTRACT
Objective To investigate the association between recent 
statin exposure and risk of severe COVID-19 infection 
and all- cause mortality in patients with COVID-19 in 
Denmark.
Design and setting Observational cohort study using 
data from Danish nationwide registries.
Participants Patients diagnosed with COVID-19 from 22 
February 2020 to 17 May 2020 were followed from date 
of diagnosis until outcome of interest, death or 17 May 
2020.
Interventions Use of statins, defined as a redeemed drug 
prescription in the 6 months prior to COVID-19 diagnosis.
Primary and secondary outcome measures All- cause 
mortality, severe COVID-19 infection and the composite.
Results The study population comprised 4842 patients 
with COVID-19 (median age 54 years (25th–75th 
percentile, 40–72), 47.1% men), of whom 843 (17.4%) 
redeemed a prescription of statins. Patients with statin 
exposure were more often men and had a greater 
prevalence of comorbidities. The median follow- up 
was 44 days. After adjustment for age, sex, ethnicity, 
socioeconomic status and comorbidities, statin exposure 
was not associated with a significantly different risk 
of mortality (HR 0.96 (95% CI 0.78 to 1.18); 30- day 
standardised absolute risk (SAR), 9.8% (8.7% to 11.0%) 
vs 9.5% (8.2% to 10.8%); SAR difference, −0.4% (−1.9% 
to 1.2%)), severe COVID-19 infection (HR 1.16 (95% CI 
0.95 to 1.41); 30- day SAR, 13.0% (11.8% to 14.2%) vs 
14.9% (12.8% to 17.1%); SAR difference, 1.9% (−0.7% to 
4.5%)), and the composite outcome of all- cause mortality 
or severe COVID-19 infection (HR 1.05 (95% CI 0.89 to 
1.23); 30- day SAR, 17.6% (16.4% to 18.8%) vs 18.2% 
(16.4% to 20.1%); SAR difference, 0.6% (−1.6% to 2.9%)). 
The results were consistent across subgroups of age, 
sex and presumed indication for statin therapy. Among 
patients with statin exposure, there was no difference 
between statin drug or treatment intensity with respect to 
outcomes.
Conclusions Recent statin exposure in patients with 
COVID-19 infection was not associated with an increased 
or decreased risk of all- cause mortality or severe infection.
INTRODUCTION
The COVID-19 pandemic, caused by 
SARS- CoV-2, is an unprecedented threat to 
global health in recent time.1 Governments 
worldwide have imposed comprehensive 
measures to prevent the rapid spread of 
SARS- CoV-2, including extensive societal 
lockdown and reorganisation of healthcare 
systems. Recently, an observational study 
demonstrated that in- hospital use of statins 
was associated with substantial improvement 
in survival among patients hospitalised with 
COVID-19.2 Specifically, the authors reported 
a relative risk reduction of 42% in in- hospital 
mortality with statin therapy. This finding 
may be biased by patient selection, treatment 
indication and residual confounding and 
therefore merits further investigation.2 In 
addition, a computer- based study suggested 
that rosuvastatin may be effective in the 
treatment of COVID-19 infection.3 However, 
other observational studies, including a meta- 
analysis, did not find any association between 
statins and improved outcomes in patients 
with COVID-19.4–6
Several mechanisms by which statins may 
exert their potential beneficial effects have 
been proposed. First, the case fatality rate 
Strengths and limitations of this study
 ► The study was based on high- quality and complete 
data from nationwide administrative registries.
 ► The Danish healthcare system provides equal ac-
cess to healthcare services for all residents regard-
less of socioeconomic or insurance status.
 ► The observational nature of this study precludes the 
assessment of cause–effect relationships.
 ► Residual confounding and confounding by indication 
cannot be excluded.
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with COVID-19 infection is substantially higher in patients 
with established cardiovascular disease and diabetes 
than those without, and there is evidence of cardiac 
involvement and myocardial injury in some patients with 
COVID-19.7–17 Given their potential cardioprotective 
effects, statins may possibly prevent myocardial injury 
and adverse cardiovascular events, particularly in patients 
with established cardiovascular disease.18 Second, beyond 
their lipid- lowering properties, statins exert various 
beneficial pleiotropic effects, including modulating the 
immune response at different levels, improving endo-
thelial function, and decreasing oxidative stress and 
inflammation.18–21 Third, some randomised clinical trials 
and observational studies—but not all—have indicated 
that statins may be associated with less severe infection 
and improved outcomes in patients with viral infec-
tions.22–31 On the other hand, experimental studies have 
suggested that statins, among other drugs, may increase 
the expression of ACE2,32–34 a membrane- bound amino-
peptidase expressed in the lungs, heart and other tissues 
that is thought to facilitate entry of SARS- CoV-2 into the 
cells.35–37 Also, case series have reported hypercholestero-
laemia to be one of the most common comorbidities in 
patients with COVID-19.38 These considerations have led 
to the concern that statins may confer a predisposition 
to more severe infection and adverse outcomes during 
COVID-19 infection. Taken together, the effect of statins 
on outcomes in patients with COVID-19 infection remains 
unclear.
In light of these uncertainties, it is important to assess 
whether statin therapy may improve the clinical course 
of patients with COVID-19 infection or lead to further 
deterioration. To address this issue, we performed a 
nationwide registry- based cohort study to investigate the 
association between recent statin exposure and the risk 
of severe COVID-19 infection and all- cause mortality in 
patients with COVID-19 infection.
METHODS
Data sources
In Denmark, all citizens are assigned a unique and 
personal identification number, which allows accurate 
linkage of nationwide administrative registries at an 
individual level. For this study, data from the following 
nationwide administrative registries were obtained: the 
Danish National Patient Registry, which contains data on 
all hospital admissions and outpatient contacts according 
to the International Classification of Diseases (ICD)39; 
the Danish National Prescription Registry, which holds 
information on dispensing date, strength and quantity of 
all claimed drug prescriptions in Denmark40; the Danish 
Civil Registration System, which holds information on 
birth date, sex and vital status (ie, whether a person is 
alive and a resident of Denmark, disappeared, emigrated 
or dead, along with the date of these events)41; and Statis-
tics Denmark, which holds data on education, household 
income and marital status.42 43 The Danish registries are 
validated, of high quality and have been described in 
detail previously.39–43
Study population
The study population comprised all Danish citizens who 
were examined at a hospital, including inpatient, outpa-
tient and emergency department visits, and had a primary 
or secondary diagnosis code for COVID-19 infection 
(ICD-10 codes: B342, B972) from 22 February 2020 until 
17 May 2020. According to the Danish Ministry of Health, 
these codes have a positive predictive value of 99%. 
Comorbidity was obtained using in- hospital and outpa-
tient diagnosis codes any time prior to diagnosis (online 
supplemental etable 1 for ICD-8 and ICD-10 codes). 
Patients with hypertension were identified using claimed 
drug prescriptions as described previously.44 45 Pharmaco-
therapy at baseline was defined as claimed prescriptions 
within 180 days prior to diagnosis (online supplemental 
eTable 2 for Anatomical Therapeutic Chemical (ATC) 
Classification System codes). The highest level of 
completed education was classified in accordance with 
the International Standard Classification of Education. 
Average household income in 2018 was calculated and 
graded in quartiles. The duration of statin treatment 
prior to COVID-19 diagnosis was determined for each 
individual during follow- up using an algorithm based on 
claimed prescriptions, taking date of claimed prescrip-
tions, dosage and packing size into account, as described 
previously.46 47
Exposure
Exposure to statins was defined as at least one redeemed 
prescription of a statin (ATC code C10AA) in the 6 
months prior to diagnosis.
Outcomes
The primary outcome was all- cause mortality. The 
secondary outcomes were (1) severe COVID-19 infection, 
defined as a hospital diagnosis of ‘COVID-19 severe acute 
respiratory syndrome’ (ICD-10 code: B972A) or admis-
sion to an intensive care unit; and (2) the composite of 
all- cause mortality or severe COVID-19 infection. Patients 
were followed from the date of diagnosis until occurrence 
of the outcome of interest, death, emigration or 17 May 
2020, whichever came first.
Statistics
Baseline characteristics were reported as frequencies 
with percentages or medians with 25th–75th percentiles. 
Differences in baseline characteristics according to statin 
exposure were tested with χ2 test for categorical variables 
and Mann- Whitney test for continuous variables. Cause- 
specific unadjusted and adjusted Cox regression models 
were used to compare outcomes according to statin expo-
sure. Adjusted models included the following variables: 
age (modelled as a restricted cubic spline with three 
knots: 10th, 50th and 90th percentile), sex, ethnicity 
(native Danish, immigrant, descendant from immigrant), 
education, income, comorbidity (ie, history of ischaemic 
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heart disease, stroke, peripheral artery disease, diabetes 
mellitus, heart failure, atrial fibrillation, hypertension, 
malignancy, chronic kidney disease, chronic obstruc-
tive pulmonary disease, liver disease) and concomitant 
medical treatment (ie, aspirin, oral anticoagulants, beta- 
blockers, calcium channel blockers, renin- angiotensin- 
aldosterone system inhibitors). Reported were HRs, 
30- day risks of outcomes standardised to the risk factor 
distribution of all patients in the sample, and differences 
of standardised 30- day risks. For the outcome severe 
COVID-19 infection, the main Cox regression model 
was combined with a Cox regression model for the rate 
of the competing risk of death without severe COVID-19 
infection.48 Interactions between statin exposure and 
clinically relevant variables (including age categories, 
sex, presumed indication for statin therapy (ie, history of 
stroke, ischaemic heart disease, peripheral artery disease, 
diabetes mellitus or familial hypercholesterolaemia)) 
on outcomes were tested for. All statistical analyses were 
performed with SAS V.9.4 statistical software and R V.3.6.1 
(The R Foundation).49 The level of statistical significance 
was set at 5%.
To test the robustness of our findings, a number of 
sensitivity analyses were performed: (1) The definition of 
statin exposure was changed from at least one redeemed 
prescription of a statin in the 6 months prior to diagnosis 
to 3 months. (2) The risk of death among patients with 
severe COVID-19 infection according to statin exposure 
was examined. (3) Among patients with statin expo-
sure, the risks of outcomes according to statin treatment 
intensity (ie, high- intensity vs moderate- intensity/low- 
intensity) were investigated. High- intensity statin therapy 
was defined as either (1) atorvastatin 40–80 mg daily, 
(2) rosuvastatin 20–40 mg daily or (3) simvastatin 80 mg 
daily. (4) Among patients with statin exposure, the risk 
of outcomes according to statin drug (ie, simvastatin, 
atorvastatin, rosuvastatin) was examined. Pravastatin 
was excluded from this analysis due to a low number of 
patients prescribed this drug. (5) The statin population 
was restricted to those with a treatment duration of at 
least 3 months.
Patient and public involvement
This research was done without patient involvement. 
Patients were not invited to comment on the study 
design and were not consulted to develop patient rele-
vant outcomes or interpret the results. Patients were not 
invited to contribute to the writing or editing of this docu-
ment for readability or accuracy.
RESULTS
In total, 4842 patients with COVID-19 infection were 
included in the study. Of these, 843 (17.4%) redeemed 
a prescription of statins within 6 months prior to diag-
nosis. The first patient was included on 22 February 2020 
and the last patient on 17 May 2020. The median age of 
the study population was 54 years (25th–75th percentile, 
40–72), and 47.1% were men. The mean duration of statin 
treatment prior to COVID-19 diagnosis was 3.6 years. The 
baseline characteristics of the patients in the groups of 
interest are summarised in table 1. Patients with statin 
exposure were older, more often men and native Danish, 
had a greater prevalence of cardiovascular and non- 
cardiovascular comorbidities, and a higher utilisation of 
medication compared with those admitted with no statin 
exposure. The median follow- up time from the date of 
COVID-19 diagnosis was 44 days (25th–75th percentile, 
29–56).
All-cause mortality, composite outcome and severe COVID-19 
infection
Unadjusted, sex- adjusted and age- adjusted, and fully 
adjusted HRs for statin exposure and outcomes are shown 
in figure 1. Table 2 displays unadjusted, sex- adjusted and 
age- adjusted, and fully adjusted standardised 30- day abso-
lute risks of outcomes according to statin exposure. In 
total, 488 (10.1%) patients died during follow- up: 177 
(21.0%) in the statin group and 311 (7.8%) in the non- 
statin group. In the unadjusted Cox regression analysis, 
statin exposure was associated with a significantly higher 
risk of mortality compared with no statin exposure (HR 
2.87 (95% CI 2.39 to 3.46)). However, when adjusting 
for age, sex, ethnicity, socioeconomic status and comor-
bidities, statin exposure was not associated with a signifi-
cantly different risk of mortality (HR 0.96 (95% CI 0.78 to 
1.18)). Similarly, the standardised absolute 30- day risk of 
all- cause mortality was not significantly different between 
groups (9.8% (8.7% to 11.0%) vs 9.5% (8.2% to 10.8%) 
in the no statin and statin exposure groups, respectively; 
standardised absolute risk difference, −0.4% (−1.9% to 
1.2%)).
During follow- up, 881 (18.2%) patients experienced 
the composite outcome of all- cause mortality or severe 
COVID-19 infection: 292 (34.6%) in the statin group 
and 589 (14.7%) in the non- statin group. Although 
statin exposure was associated with a significantly higher 
risk of the composite outcome compared with no statin 
exposure in the unadjusted Cox regression analysis (HR 
2.57 (95% CI 2.34 to 2.96)), statin exposure was not 
associated with a significantly different risk of mortality 
in the fully adjusted analysis (HR 1.05 (95% CI 0.89 to 
1.23)). Similarly, the standardised absolute 30- day risk 
of the composite outcome was not significantly different 
between groups (17.6% (16.4% to 18.8%) vs 18.2% 
(16.4% to 20.1%) in the no statin and statin exposure 
groups, respectively; standardised absolute risk differ-
ence, 0.6% (−1.6% to 2.9%)).
In total, 623 (12.9%) patients developed severe 
COVID-19 infection during follow- up: 204 (24.2%) in the 
statin group and 419 (10.5%) in the non- statin group. In 
the unadjusted Cox regression analysis, statin exposure 
was associated with a significantly higher risk of severe 
COVID-19 infection compared with no statin exposure 
(HR 2.41 (95% CI 2.04 to 2.85)). However, in the fully 
adjusted analysis, statin exposure was not associated with 
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a significantly different risk of severe COVID-19 infec-
tion (HR 1.16 (95% CI 0.95 to 1.41)). Similarly, the 
standardised absolute 30- day risk of severe COVID-19 
infection was not significantly different between groups 
(13.0% (11.8% to 14.2%) vs 14.9% (12.8% to 17.1%) in 
the no statin and statin exposure groups, respectively; 
standardised absolute risk difference, 1.9% (−0.7% to 
4.5%)).
Subgroup and sensitivity analyses
The results of the prespecified subgroup analyses for the 
primary and secondary outcomes are displayed in table 3. 
In all subgroups, statin exposure was not associated 
with a significantly different risk of all- cause mortality, 
a composite of all- cause mortality or severe COVID-19 
infection, and COVID-19 infection (p for interaction 
>0.23 for all subgroups).
To test the robustness of the findings, we performed a 
number of sensitivity analyses. (1) The definition of statin 
exposure was changed from as at least one redeemed 
prescription of a statin in the 6 months prior to diagnosis 
to 3 months. In total, 646 (13.3%) patients redeemed a 
prescription of a statin within 3 months. Among those who 
redeemed a statin prescription within 6 months, but not 
within 3 months, 82.2% redeemed a prescription of 100 
tablets or more. In this analysis, statin exposure was not 
associated with a significantly different risk of all- cause 
mortality (adjusted HR 0.97 (95% CI 0.78 to 120); stan-
dardised absolute 30- day risk difference, −0.2% (−1.8% 
to 1.3%)), a composite of all- cause mortality or severe 
COVID-19 infection (adjusted HR 1.06 (95% CI 0.90 to 
1.26); standardised absolute 30- day risk difference, 0.9% 
(−1.4% to 3.3%)), or severe COVID-19 infection (adjusted 
HR 1.18 (95% CI 0.97 to 1.45); standardised absolute 
30- day risk difference, 2.3% (−0.4% to 5.1%)). (2) The 
risk of death among patients with severe COVID-19 infec-
tion according to statin exposure was examined. In this 
analysis, statin exposure was not associated with a signifi-
cantly different risk of all- cause mortality (adjusted HR 
0.91 (95% CI 0.65 to 1.27)). (3) Among patients with 
statin exposure, the risks of outcomes according to 
intensity of statin therapy were investigated. In total, 305 
(36.2%) patients received high- intensity statin therapy. 
Compared with moderate- intensity/low- intensity therapy, 
high- intensity statin therapy was not associated with a 
Table 1 Baseline characteristics of patients with COVID-19 
with and without statin exposure
No statin 
exposure
n=3999
Statin 
exposure
n=843
Demographics   
  Age, median (25th–75th 
percentile)
50 (37–65) 73 (63–79)
  Age, n (%)   
  <50 years 1965 (49.1) 40 (4.7)
  50–70 years 1246 (31.2) 307 (36.4)
  >71 years 788 (19.7) 496 (58.8)
  Male, n (%) 1766 (44.2) 515 (61.1)
  Ethnicity, n (%)   
  Native Danish 3270 (81.8) 729 (86.5)
  Immigrant 610 (15.2) 110 (13.0)
  Descendant from immigrant 119 (3.0) 4 (0.5)
Socioeconomic status   
  Education, n (%)   
  Basic school 980 (24.5) 294 (34.9)
  High school/vocational 
education
1427 (35.7) 369 (43.8)
  Short/medium higher 
education
506 (12.6) 53 (6.3)
  Long higher education 1086 (27.2) 127 (15.1)
  Income group, n (%)   
  Q1 (lowest) 987 (24.7) 223 (26.4)
  Q2 922 (23.0) 289 (34.3)
  Q3 1003 (25.1) 208 (24.7)
  Q4 (highest) 1087 (27.2) 123 (14.6)
Comorbidities, n (%)   
  Ischaemic heart disease 182 (4.6) 262 (31.1)
  Stroke 95 (2.4) 119 (14.1)
  Peripheral artery disease 35 (0.9) 51 (6.0)
  Diabetes 188 (4.7) 230 (27.3)
  Heart failure 98 (2.5) 85 (10.1)
  Atrial fibrillation 206 (5.2) 144 (17.1)
  Hypertension 491 (12.3) 452 (53.6)
  Malignancy 345 (8.6) 147 (17.4)
  Chronic kidney disease 127 (3.2) 104 (12.3)
  Chronic obstructive 
pulmonary disease
142 (3.6) 80 (9.5)
  Liver disease 95 (2.4) 18 (2.1)
Concomitant medical 
treatment, n (%)
  
  Aspirin 132 (3.3) 238 (28.2)
  Oral anticoagulants 222 (5.6) 169 (20.0)
  Beta- blockers 283 (7.1) 303 (35.9)
  Calcium channel blockers 282 (7.1) 247 (29.3)
  RAAS inhibitors 522 (13.1) 438 (52.0)
Type of statin, n (%)   
Continued
No statin 
exposure
n=3999
Statin 
exposure
n=843
  Atorvastatin N/A 426 (50.5)
  Simvastatin N/A 351 (41.7)
  Rosuvastatin N/A 57 (6.8)
  Pravastatin N/A 9 (1.0)
N/A, not applicable; RAAS, renin- angiotensin- aldosterone system 
inhibitors.
Table 1 Continued
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significantly different risk of all- cause mortality (adjusted 
HR 1.07 (95% CI 0.77 to 1.50)), a composite of all- cause 
mortality or severe COVID-19 infection (adjusted HR 
0.95 (95% CI 0.73 to 1.22)), or severe COVID-19 infec-
tion (adjusted HR 0.81 (95% CI 0.60 to 1.10)). (4) Among 
patients with statin exposure, the risks of outcomes 
according to statin drug were investigated. Compared with 
simvastatin, atorvastatin and rosuvastatin were not associ-
ated with a significantly different risk of all- cause mortality 
(atorvastatin: adjusted HR 0.99 (95% CI 0.72 to 1.37); 
rosuvastatin: adjusted HR 0.43 (95% CI 0.15 to 1.19)), a 
composite of all- cause mortality or severe COVID-19 infec-
tion (atorvastatin: adjusted HR 0.91 (95% CI 0.71 to 1.17); 
rosuvastatin: adjusted HR 0.90 (95% CI 0.53 to 1.54)), or 
severe COVID-19 infection (atorvastatin: adjusted HR 
0.80 (95% CI 0.60 to 1.08); rosuvastatin: adjusted HR 1.03 
(95% CI 0.59 to 1.82)). (5) The statin population was 
restricted to those with a treatment duration of at least 3 
months. Excluding patients in the statin group with a treat-
ment duration less than 3 months, the population yielded 
similar findings as the main results (all- cause mortality, 
adjusted HR 1.00 (95% CI 0.81 to 1.24); a composite of 
all- cause mortality or severe infection, 1.09 (0.92 to 1.29); 
severe COVID-19 infection, 1.19 (0.97 to 1.47)).
Figure 1 HR for all- cause mortality, a composite of severe COVID-19 infection or all- cause mortality, and severe COVID-19 
infection according to statin exposure. Adjusted for age, sex, ethnicity, education, income, comorbidity (ie, history of ischaemic 
heart disease, stroke, peripheral artery disease, diabetes mellitus, heart failure, atrial fibrillation, hypertension, malignancy, 
chronic kidney disease, chronic obstructive pulmonary disease, liver disease) and concomitant medical treatment (ie, aspirin, 
oral anticoagulants, beta- blockers, calcium channel blockers, renin- angiotensin- aldosterone system inhibitors).
Table 2 Standardised 30- day absolute risks and risk differences for all- cause mortality, a composite of severe COVID-19 
infection or all- cause mortality, and severe COVID-19 infection according to statin exposure
No statin exposure
30- day risk, % (95% CI)
Statin exposure
30- day risk, % (95% CI)
30- day risk difference, % (95% 
CI)
All- cause mortality
  Unadjusted 7.5 (6.6 to 8.3) 20.0 (17.4 to 22.6) 12.5 (9.8 to 15.2)
  Age- adjusted and sex- 
adjusted
9.6 (8.4 to 10.7) 10.0 (8.7 to 11.3) 0.4 (−1.1 to 1.9)
  Fully adjusted* 9.8 (8.7 to 11.0) 9.5 (8.2 to 10.8) −0.4 (−1.9 to 1.2)
Composite outcome
  Unadjusted 14.7 (13.6 to 15.8) 34.2 (31.2 to 37.2) 19.6 (16.3 to 22.8)
  Age- adjusted and sex- 
adjusted
17.1 (16.0 to 18.3) 19.4 (17.6 to 21.3) 2.3 (0.1 to 4.5)
  Fully adjusted* 17.6 (16.4 to 18.8) 18.2 (16.4 to 20.1) 0.6 (−1.6 to 2.9)
Severe COVID-19 infection
  Unadjusted 10.8 (9.8 to 11.8) 25.6 (22.6 to 28.7) 14.9 (11.5 to 18.2)
  Age- adjusted and sex- 
adjusted
12.7 (11.5 to 13.8) 15.8 (13.7 to 17.9) 3.2 (0.7 to 5.7)
  Fully adjusted* 13.0 (11.8 to 14.2) 14.9 (12.8 to 17.1) 1.9 (−0.7 to 4.5)
*Adjusted for age, sex, ethnicity, education, income, comorbidity (ie, history of ischaemic heart disease, stroke, peripheral artery disease, 
diabetes mellitus, heart failure, atrial fibrillation, hypertension, malignancy, chronic kidney disease, chronic obstructive pulmonary disease, 
liver disease) and concomitant medical treatment (ie, aspirin, oral anticoagulants, beta- blockers, calcium channel blockers, renin- angiotensin- 
aldosterone system inhibitors).
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DISCUSSION
In this Danish nationwide cohort study, we investigated 
the association between recent statin exposure and the 
risk of all- cause mortality or severe infection, individually 
and as a composite, in patients with COVID-19 infection. 
The main finding of this study was that statin exposure 
prior to COVID-19 diagnosis was not associated with an 
improvement or deterioration in the clinical course of 
patients with COVID-19 infection, and this was consistent 
across clinically relevant subgroups.
In a recent observational study using data from 21 
hospitals in Hubei Province, China, Zhang et al 2 demon-
strated that in- hospital use of statins was associated with 
improved survival among patients hospitalised with 
COVID-19. Specifically, the authors found a 28- day 
mortality risk of 5.2% and 9.4% in the statin and non- 
statin user groups, respectively, and that in- hospital use 
of statins was associated with a 42% decrease in in- hos-
pital mortality.2 Although the data may be biased by 
patient selection, treatment indication and residual 
confounding, including lack of adjustment for socioeco-
nomic status and prehospital medication, this contro-
versial finding merits further investigation. In addition, 
Farag et al3 performed a computer- based study and used 
a structure- based drug design to screen more than 2000 
Food and Drug Administration- approved drugs against 
SARS- CoV-2 main protease enzyme substrate- binding 
pocket. Other than antiviral drugs, the authors also iden-
tified rosuvastatin as a drug that may be useful against 
SARS- CoV-2. On the other hand, other observational 
studies, including a meta- analysis, did not find an asso-
ciation between statin therapy and improved outcomes 
in patients with COVID-19.4–6 In our nationwide cohort 
study including all patients with COVID-19, irrespective 
of hospitalisation status, we did not find any association 
between statin use prior to diagnosis and the risk of all- 
cause mortality or severe COVID-19 infection, individ-
ually and as a composite. These results were consistent 
across clinically relevant subgroups, including age, sex 
and presumed indication for statin therapy. In addition, 
among patients using statins, type of statin drug did not 
significantly modify the risk of outcomes, although there 
was a trend towards a lower risk of all- cause mortality with 
rosuvastatin. Further studies are warranted to establish 
whether rosuvastatin may improve outcomes in patients 
with COVID-19 infection. Taken together, our study does 
not provide evidence of a beneficial effect of statin expo-
sure prior to COVID-19 diagnosis.
Several hypotheses have been proposed in relation to 
the role of statin therapy in patients with COVID-19. It 
has been proposed that statins may improve the clinical 
course in patients with COVID-19, and several mecha-
nisms by which statins exert their potential beneficial 
effects have been proposed. For example, reports of 
cardiac involvement during the course of the infection, 
particularly in severe cases, have emerged,7–17 and it has 
been hypothesised that statins, at least to some extent, 
may prevent or decrease the likelihood of myocardial 
injury and cardiovascular events.18 Further, statins may 
modulate the immune response, improve endothelial 
function, and decrease oxidative stress and inflammation 
and thereby predispose to less severe infection and better 
outcomes.18–21 Data on such effects of statins in humans, 
however, are conflicting. While some randomised trials 
Table 3 Fully adjusted HR for all- cause mortality, a composite of severe COVID-19 infection or all- cause mortality, and severe 
COVID-19 infection according to statin exposure in subgroups
Mortality
HR (95% CI)
Composite outcome
HR (95% CI)
Severe COVID-19 infection
HR (95% CI)
Overall 0.96 (0.78 to 1.18) 1.05 (0.89 to 1.23) 1.16 (0.95 to 1.41)
Age categories
  <50 years N/A 0.50 (0.11 to 2.21) 0.50 (0.11 to 2.22)
  50–70 years 0.55 (0.29 to 1.08) 1.00 (0.72 to 1.40) 1.06 (0.74 to 1.50)
  >70 years 1.02 (0.82 to 1.28) 1.05 (0.87 to 1.28) 1.09 (0.85 to 1.41)
Sex
  Male 1.06 (0.81 to 1.37) 1.03 (0.84 to 1.26) 1.04 (0.82 to 1.33)
  Female 0.78 (0.54 to 1.13) 1.07 (0.81 to 1.42) 1.39 (0.98 to 1.99)
Presumed indication for statin therapy
  Yes 0.90 (0.68 to 1.20) 1.00 (0.79 to 1.26) 1.16 (0.86 to 1.57)
  No 0.98 (0.71 to 1.36) 1.03 (0.81 to 1.30) 1.07 (0.81 to 1.41)
Reference group: no statin exposure.
Adjusted for age, sex, ethnicity, education, income, comorbidity (ie, history of ischaemic heart disease, stroke, peripheral artery disease, 
diabetes mellitus, heart failure, atrial fibrillation, hypertension, malignancy, chronic kidney disease, chronic obstructive pulmonary disease, 
liver disease) and concomitant medical treatment (ie, aspirin, oral anticoagulants, beta- blockers, calcium channel blockers, renin- angiotensin- 
aldosterone system inhibitors).
All p values for differences within subgroups were not statistically significant (>0.23).
N/A, not applicable.
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and observational studies have demonstrated possible 
benefits of statins in reducing mortality and improving 
the clinical course of patients with severe infections, 
particularly viral infections, others have not found any 
beneficial effects of statins in this setting.22–31 On the 
other hand, preclinical studies have suggested that statins 
upregulate the expression of ACE2, an enzyme thought 
to facilitate entry of SARS- CoV-2 into the cells, although 
this hypothesis has not been proven in humans.32–34 
Moreover, hypercholesterolaemia has been reported to 
be one of the most common comorbidities in patients 
with COVID-19, although the majority of these case series 
did not report data on medication, including statins.38 
These considerations had led to the hypothesis that 
statins confer a greater risk of more severe infection and 
adverse outcomes during COVID-19 infection. In light of 
these concerns, it is reassuring that statins were not asso-
ciated with a deterioration in the clinical course of these 
patients in our study. Taken together, our findings do 
not support discontinuation of statin therapy in patients 
with an indication for statins. However, it is important 
to emphasise the inherent limitations of observational 
studies, including residual confounding, confounding 
by indication and inadequate assessment of causal infer-
ence. There is, therefore, a need for further studies to 
establish the role of statins in patients with COVID-19 
with and without an indication for statin therapy. Several 
randomised clinical trials have been initiated to assess this 
clinically relevant issue, and the results from these trials 
are anticipated.50–53
Another potential concern with statins during 
COVID-19 infection is liver injury. Reports of liver injury 
during the course of the infection, particularly in severe 
cases, have emerged.54–56 Although statins are generally 
considered to be safe and well tolerated, in rare cases, 
these medications may also induce liver injury.57 Conse-
quently, the European Society of Cardiology guidelines 
for the diagnosis and management of cardiovascular 
disease during the COVID-19 pandemic recommend 
withholding statin therapy temporarily in patients with 
COVID-19 with increased liver enzymes.58 Whether statin 
therapy confers an increased risk of liver injury and subse-
quent adverse outcomes during COVID-19 infection has 
not been established. Our study did not allow for a direct 
assessment of this issue due to lack of data on in- hospital 
medication and laboratory findings. Nevertheless, it is 
reassuring that statin exposure prior to diagnosis was 
not associated with an increased risk of worse outcomes 
in patients with COVID-19. Further studies, preferably 
randomised controlled trials, are needed to clarify the 
association between statin therapy and liver injury on 
subsequent outcomes during COVID-19 infection.
Strengths and limitations
The main strength of this study is the completeness of 
data from nationwide administrative registries. The 
Danish healthcare system, funded by taxes, provides equal 
access to healthcare services for all residents regardless of 
socioeconomic or insurance status. In Denmark, statins 
can be purchased only through prescription. Due to 
partial reimbursement of drug expenses by the Danish 
healthcare system, pharmacies are required to register all 
redeemed prescriptions ensuring complete and accurate 
registration. The findings of this study should be viewed 
in the context of a number of limitations. The observa-
tional nature of this study precludes the assessment of 
cause–effect relationships; thus, only associations are 
reported. Residual confounding cannot be excluded 
despite adjustment for potential confounders, and it is 
likely that these adjustments were not sufficient to even 
out the differences between the groups. For example, 
mounting evidence suggests that patients with COVID-19 
may develop clinically significant coagulopathy with fatal 
thromboembolic complications,59–61 and more statin 
users were treated with aspirin and oral anticoagulants 
compared with non- statin users. Although we attempted 
to minimise the impact of these differences by adjusting 
for concomitant medication, including aspirin and oral 
anticoagulants, in the fully adjusted analyses, we cannot 
exclude the possibility that these differences may have 
had an impact on the association between statin use and 
outcomes. In addition, confounding by indication cannot 
be omitted in pharmacoepidemiological studies despite 
our attempt to minimise the impact of this limitation by 
performing several subgroup analyses (eg, patients with 
or without a presumed indication for statin therapy). We 
did not have laboratory data to confirm a positive swab 
test for COVID-19. However, coding of both tested indi-
viduals with tentative diagnosis codes and those with posi-
tive swabs with definite diagnosis codes have been and are 
systematically performed in Denmark, and the Danish 
Ministry of Health have indicated a positive predictive 
value of 99% of these codes. Compared with the official 
COVID-19 case numbers in Denmark, this study included 
fewer cases because ICD-10 codes capture only those 
patients who were diagnosed in the hospital system (inpa-
tient, outpatient or emergency department visits) and 
not in dedicated COVID-19 diagnostic kiosks. It is there-
fore possible that some patients with no or few symptoms 
may not have been captured by our ICD-10 codes. The 
outcomes examined in this study were clinically relevant 
‘hard’ endpoints. Although it would have been interesting 
to examine the association between recent statin expo-
sure and symptom improvement in patients with COVID-
19, data on symptoms were not available. In addition, due 
to lack of data on in- hospital medication, we were not able 
to investigate the impact of in- hospital statin therapy on 
outcomes. Likewise, data on statin treatment (dis)contin-
uation after the COVID-19 diagnosis were not available, 
although it was encouraged to continue statin treatment 
at the Danish hospitals. Exposure to statins was defined by 
redeemed prescriptions in the 6 months prior to diagnosis, 
although similar results were yielded when restricting this 
definition from 6 months to 3 months. It is possible that 
some patients may discontinue statin treatment prior to 
diagnosis due to early symptoms of COVID-19 infection. 
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However, we believe that this number is likely to be low, as 
the mainstream media and professional medical societies 
have not raised questions about statin treatment in the 
setting of COVID-19 to the same extent as, for example, 
ACE inhibitors/angiotensin receptor blocker treatment. 
Finally, data on whether patients were prescribed statins 
for primary or secondary prevention were not available. 
However, restricting the study population to patients with 
a presumed indication for statin therapy (ie, history of 
stroke, ischaemic heart disease, peripheral artery disease, 
diabetes mellitus or familial hypercholesterolaemia) 
yielded similar findings as the main analyses.
CONCLUSIONS
In this Danish nationwide cohort study, recent statin 
exposure in patients with COVID-19 infection was not 
associated with an increased or decreased risk of all- cause 
mortality or severe infection. Hence, our study does not 
suggest benefit or harm of statin therapy in patients 
with COVID-19. However, further studies are needed to 
establish the role of statins in patients with COVID-19 
with and without an indication for statin therapy. Several 
randomised clinical trials have been initiated to assess this 
clinically relevant issue in patients with COVID-19, and 
the results from these trials are anticipated.
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